Inhibrx Inc (INBX)
34.09
-0.29
(-0.84%)
USD |
NASDAQ |
Apr 25, 16:00
34.11
+0.02
(+0.06%)
After-Hours: 20:00
Inhibrx Revenue (Quarterly): 1.634M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.634M |
| September 30, 2023 | 0.119M |
| June 30, 2023 | 0.03M |
| March 31, 2023 | 0.017M |
| December 31, 2022 | 0.274M |
| September 30, 2022 | 0.278M |
| June 30, 2022 | 0.711M |
| March 31, 2022 | 0.915M |
| December 31, 2021 | 2.836M |
| September 30, 2021 | 2.508M |
| June 30, 2021 | 0.918M |
| Date | Value |
|---|---|
| March 31, 2021 | 0.863M |
| December 31, 2020 | 2.776M |
| September 30, 2020 | 5.826M |
| June 30, 2020 | 3.334M |
| March 31, 2020 | 0.872M |
| December 31, 2019 | 0.267M |
| September 30, 2019 | 0.794M |
| June 30, 2019 | 1.00M |
| March 31, 2019 | 7.032M |
| June 30, 2018 | 2.50M |
| March 31, 2018 | 2.50M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.017M
Minimum
Mar 2023
5.826M
Maximum
Sep 2020
1.367M
Average
0.872M
Median
Mar 2020
Revenue (Quarterly) Benchmarks
| Johnson & Johnson | 21.38B |
| Gilead Sciences Inc | 7.114B |
| Outlook Therapeutics Inc | -- |
| Axonics Inc | 109.74M |
| NovaBay Pharmaceuticals Inc | 3.727M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -93.60M |
| Total Expenses (Quarterly) | 89.92M |
| EPS Diluted (Quarterly) | -1.82 |
| Enterprise Value | 1.545B |
| Profit Margin (Quarterly) | -5.73K% |
| Earnings Yield | -15.02% |
| Normalized Earnings Yield | -15.02 |